MDLN

Medline
D

MDLN

Arincen64/100B

Medline income statement 2022–2026

30.68B USD over the last twelve months, and 28.43B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
26 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
Revenue
30.68B28.43B25.51B23.23B21.45B
Revenue growth
—+11.47%+9.80%+8.31%—
Cost of revenue
22.96B20.91B19.22B18.01B16.89B
Gross profit
7.72B7.52B6.29B5.22B4.56B
Gross margin
25.16%26.44%24.66%22.48%21.25%
Research and development
——67.00M60.00M58.00M
Selling, general and administrative
5.05B4.52B4.04B3.81B3.62B
Operating expenses
5.98B5.31B4.15B3.97B3.69B
1.74B2.21B2.15B1.25B870.00M
Operating income growth
—+3.08%+71.68%+43.68%—
Operating margin
5.68%7.78%8.41%5.38%4.06%
Interest income
——280.00M237.00M27.00M
Interest expense
664.00M812.00M1.31B1.38B911.00M
Other non-operating income
-624.00M-964.00M-979.00M-1.18B-860.00M
Pretax income
1.12B1.25B1.25B264.00M10.00M
Income tax
242.00M91.00M46.00M30.00M35.00M
Effective tax rate
21.65%7.29%3.69%11.36%350.00%
564.00M1.16B1.20B234.00M-25.00M
Net income growth
—-3.42%+412.82%——
Net margin
1.84%4.08%4.70%1.01%-0.12%
Basic shares
841.12M812.00M787.12M787.12M787.12M
Diluted shares
953.60M812.00M787.12M787.12M787.12M
Change in diluted shares
—+3.16%0.00%0.00%—
EPS (basic)
0.671.431.520.30-0.03
EPS (diluted)
0.67-0.011.520.30-0.03
EPS growth
—-100.66%+406.67%——
EBITDA
2.57B2.26B3.53B2.59B1.85B
EBITDA margin
8.36%7.95%13.85%11.15%8.64%
EBIT
1.59B1.25B2.56B1.64B921.00M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Medline's income statement

Source: Financial Modeling Prep